Non-small Cell Lung Cancer

Temodar for Kidney Cancer

Personalized medicine approach tests individual cancers and chooses treatments based on this testing. Temodar is one of the drugs that is usually included in chemosensitivity panels. Sometimes, it is recommended to renal cell cancer patients based on such testing. Unfortunately, this new paradigm does not "fit" well with the existing approaches and methods for weighing and evaluating evidence supporting cancer treatments, and new approaches to do

Read more
Irinotecan for brain metastases of lung and breast cancer

Because irinotecan penetrates the brain-blood barrier and has an effect in primary brain cancer, there is some interest in using it for brain metastasis, especially for lung cancer and breast cancer. Most studies of irinotecan had been for brain mets of small(SCLC) and non-small cell lung cancer(NSMCLC) and not breast cancer and have had mixed results. One study enrolled several different cancer types and reported complete responses with irinotecan-based

Read more
Axitinib and sorafenib for thyroid cancer

Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Axitinib has been studied for thyroid cancer. Two phase II studies were reported in the Journal of Clinical Oncology evaluating different axitinib and sorafenib therapies in patients with advanced thyroid cancer have special significance. Eligible patients in both studies included

Read more
Stereotactic radiosurgery of lung

Stereotactic body radiation therapy (SBRT) is a technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions. Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) initially was used successfully forbrain cacners and malformations, orbital, and base of skull

Read more
SAMSA – A New Drug for Low Sodium

SAMSCA(tolvaptan) is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (low blood serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). The latter condition occurs with lung cancer, especially small lung cancer, and less commonly

Read more
Tarceva for Maintenance in Non-small Cell Lung Cancer

Tarceva (erlotinib) is FDA approved for non-small cell lung cancer after standard chemo has failed. Older studies showed that it does not contribute to chemotherapy in first-line. It is being studied for first line therapy of lung cancer instead of chemotherapy. This drug has been studied primarily in stage IV, when it has spread but recently it has been also studied, for maintenance, once treatment with chemotherapy had stopped. Maintenance means

Read more